Bing

SEARCH HISTORY

The stock has generated almost 880% in the last five years ... Rothblatt, Chairman & Co-CEO of United Therapeutics (NASDAQ:UTHR), sold 2,592 shares at $155.36. The total value of the transaction was $402,682. Intercept Insider Sells - Nicole Williams ...
Seeking Alpha · 8/25/2015
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2015 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review …
Financial Content · 8/19/2015
Priority Review
This continues the recent downtrend for UTHR, as the stock is now down nearly 10.9% in the past one-month time frame. This slump shouldn’t be too much of a surprise to investors, as the company has seen one negative revision in the past few weeks …
Yahoo Finance · 6/16/2014
United Therapeutics (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 2,211 shares of the company’s stock in a transaction that occurred on Wednesday, July 22nd. The stock was sold at an average price of $174.55, for a total value of $385,930.05.
Watch List News · 7/24/2015
Analyst Raj Mehra of Auriga USA maintains his "buy" rating on United Therapeutics (NASDAQ: UTHR), while raising his estimates for the company. The target price for UTHR has been raised from $54 to $70. According to Auriga USA, United …
Benzinga · ByMonica Gerson · 1/13/2010
The negative recommendation gained significant attention considering UTHR's stock was up 50% over the prior six months, and 12 of the 15 analysts on the Street that cover the stock rated the shares a Buy. Jason's Sell call is one of only two negative ...
ZACKS · 11/17/2008
This analysis was compiled based on yesterday's trading activity as we search for stocks that have could possible underperform ... and United Therapeutics (NASDAQ:UTHR) ranks third with a loss of 2.63%. Inovio Biomedical (AMEX:INO) follows with a loss ...
Financial News Network Online · ByPeter Chu · 7/31/2015
Within this sub-industry, one stock that has been a strong performer this Fall is United Therapeutics Corp (UTHR). Ever since August 29th when a US District Court judge made a favorable ruling on patents over the Remodulin drug, UTHR has been on fire.
Stockhouse · 10/21/2014
United Therapeutics Corporation ($UTHR) experienced unusually high volume on Mar. 25, as the stock lost 6.5% to a closing price of $167.85. The stock saw 1.19 million shares trade hands over the course of the day on 11,527 trades. Given that the …
Equities · 3/25/2015
What: Shares of United Therapeutics (NASDAQ: UTHR ) , a biopharmaceutical company that develops ... make up for the eventual loss of exclusivity on Remodulin, then chasing the stock higher after today may not be the best idea. United Therapeutics may ...
The Motley Fool · BySean Williams · 8/30/2014